Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

OBJECTIVES: To examine 2-year safety, efficacy and radiographic outcomes of sarilumab in adults with RA and inadequate response to MTX (MTX-IR). METHODS: In the randomized, placebo-controlled MOBILITY trial, MTX-IR patients received subcutaneous sarilumab (150 or 200 mg) or placebo every 2 weeks (q2...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C, van Adelsberg, Janet, Fan, Chunpeng, Graham, Neil M H, van Hoogstraten, Hubert, Parrino, Janie, Mangan, Erin K, Spindler, Alberto, Huizinga, Tom W J, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055572/
https://www.ncbi.nlm.nih.gov/pubmed/29746672
http://dx.doi.org/10.1093/rheumatology/key121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055572/
https://www.ncbi.nlm.nih.gov/pubmed/29746672
http://dx.doi.org/10.1093/rheumatology/key121

Ejemplares similares